Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting
Pratteln, Switzerland, March 2, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy dkoding.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dkoding.in Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the